Cybin to Participate in Upcoming Scientific and Investor Conferences
-
Doug Drysdale , Cybin’s Chief Executive Officer, participated in a panel discussion titled “Trials to Treatments” at10:00 a.m. Central European Time onWednesday, September 21, 2022 .
-
Amir Inamdar , MBBS, DNB (Psych), MFPM, Cybin’s Chief Medical Officer, will participate in a panel discussion titled “Where Psychedelics Science Meets Business” at10:30 a.m. Central European Time onSaturday, September 24, 2022 . For more information on how to access the event, please click here. -
Bill Brennan , Ph.D., Co-Author of EMBARK, and a core faculty and clinical supervisor, will deliver a presentation on Cybin’s psychedelic-assisted psychotherapy model titled “Introducing EMBARK: a trans-diagnostic, trans-drug model of psychedelic-assisted psychotherapy and therapist training” at2:40 p.m. Central European Time onFriday, September 23, 2022 .
Jefferies Innovation in Mental Health Summit,
-
Leah Gibson , Cybin’s Vice President ofIR & Strategic Communications , will host investor meetings. If you plan on attending the conference, please reach out to your Jefferies representative to request a meeting.
-
Doug Drysdale , Cybin’s Chief Executive Officer, will participate in a panel discussion and host investor meetings. If you plan on attending the conference, please reach out to your Cantor representative to request a meeting.
About
View source version on businesswire.com: https://www.businesswire.com/news/home/20220921005282/en/
Investor & Media:
Vice President, Investor Relations
irteam@cybin.com – or – media@cybin.com
Chief Legal Officer
1-866-292-4601
Source: